Central rho kinase inhibition restores baroreflex sensitivity and angiotensin ii type 1 receptor protein imbalance in conscious rabbits with chronic heart failure

Hypertension

Volumn 61, Issue 3, 2013, Pages 723-729

  Haack, Karla K V ^a   Gao, Lie ^a   Schiller, Alicia M ^a   Curry, Pamela L ^a   Pellegrino, Peter R ^a   Zucker, Irving H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

angiotensin AT1 receptor; autonomic nervous system; heart failure; NO synthase; rho associated kinase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; FASUDIL; METOPROLOL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN STEM; CONFERENCE PAPER; CONTROLLED STUDY; HEART EJECTION FRACTION; HEART FAILURE; HEART PACING; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTING HEART RATE; SENSITIVITY ANALYSIS; SYMPATHETIC TONE; VAGUS TONE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BAROREFLEX; BRAIN STEM; CHRONIC DISEASE; CONSCIOUSNESS; ENZYME INHIBITORS; HEART; HEART FAILURE; HEART RATE; MALE; METOPROLOL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; PHENYLEPHRINE; RABBITS; RECEPTOR, ANGIOTENSIN, TYPE 1; RHO-ASSOCIATED KINASES; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE;

EID: 84874394223     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00396     Document Type: Conference Paper

References (54)

1. Zucker IH. Neural control of the circulation in heart failure and coronary ischaemia: introduction. Clin Exp Pharmacol Physiol. 1996;23:685-687.
2. Schultz HD. Nitric oxide regulation of autonomic function in heart failure. Curr Heart Fail Rep. 2009;6:71-80.
3. Sawada N, Liao JK. Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Rev Neurother. 2009;9:1171-1186.
4. Adam O, Laufs U. Antioxidative effects of statins. Arch Toxicol. 2008;82:885-892.
5. Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002;942:23-30.
6. Kim WY, Gonsiorek EA, Barnhart C, Davare MA, Engebose AJ, Lauridsen H, Bruun D, Lesiak A, Wayman G, Bucelli R, Higgins D, Lein PJ. Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation. J Neurochem. 2009;108:1057-1071.
7. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011;32:167-173.
8. Hirooka Y, Shimokawa H, Takeshita A. Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect. 2004;17:523-527.
9. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol. 2011;31:1898-1907.
10. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res. 1998;82:666-676.
11. Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y, Matsuoka H. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther. 2002;301:459-466.
12. Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
13. Aghajanian A, Wittchen ES, Campbell SL, Burridge K. Direct activation of RhoA by reactive oxygen species requires a redox-sensitive motif. PLoS ONE. 2009;4:e8045.
14. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, Tsukita S. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol. 1998;140:647-657.
15. Ito K, Hirooka Y, Kishi T, Kimura Y, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension. 2004;43:156-162.
16. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307-1310.
17. Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol. 2011;300:F31-F39.
18. do Carmo JM, Bassi M, da Silva AA, Hall JE. Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. Hypertension. 2011;57:428-434.
19. Mousa TM, Gao L, Cornish KG, Zucker IH. Effects of angiotensin II on autonomic components of nasopharyngeal stimulation in male conscious rabbits. J Appl Physiol. 2005;98:1607-1611.
20. Kar S, Gao L, Belatti DA, Curry PL, Zucker IH. Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure. Hypertension. 2011;58:627-634.
21. Haack KK, Engler CW, Papoutsi E, Pipinos II, Patel KP, Zucker IH. Parallel changes in neuronal AT1R and GRK5 expression following exercise training in heart failure. Hypertension. 2012;60:354-361.
22. Zucker IH. Brain angiotensin II: new insights into its role in sympathetic regulation. Circ Res. 2002;90:503-505.
23. Pliquett RU, Cornish KG, Zucker IH. Statin therapy restores sympathovagal balance in experimental heart failure. J Appl Physiol. 2003;95:700-704.
24. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation. 2005;112:1763-1770.
25. Deo SH, Fisher JP, Vianna LC, Kim A, Chockalingam A, Zimmerman MC, Zucker IH, Fadel PJ. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure. Am J Physiol Heart Circ Physiol. 2012;303:H377-H385.
26. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell. 2000;103:227-238.
27. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005;16:624-629.
28. Zhang K, Patel KP. Effect of nitric oxide within the paraventricular nucleus on renal sympathetic nerve discharge: role of GABA. Am J Physiol. 1998;275(3 pt 2):R728-R734.
29. Krukoff TL. Central actions of nitric oxide in regulation of autonomic functions. Brain Res Brain Res Rev. 1999;30:52-65.
30. Li DP, Chen SR, Pan HL. Nitric oxide inhibits spinally projecting paraventricular neurons through potentiation of presynaptic GABA release. J Neurophysiol. 2002;88:2664-2674.
31. Hirooka Y. Adenovirus-mediated gene transfer into the brain stem to examine cardiovascular function: role of nitric oxide and Rho-kinase. Prog Biophys Mol Biol. 2004;84:233-249.
32. Ito K, Hirooka Y, Hori N, Kimura Y, Sagara Y, Shimokawa H, Takeshita A, Sunagawa K. Inhibition of rho-kinase in the nucleus tractus solitarius enhances glutamate sensitivity in rats. Hypertension. 2005;46:360-365.
33. Ito K, Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Activation of Rhokinase in the brainstem enhances sympathetic drive in mice with heart failure. Auton Neurosci. 2008;142:77-81.
34. Daubert DL, Liu D, Zucker IH, Brooks VL. Roles of nitric oxide and angiotensin II in the impaired baroreflex gain of pregnancy. Am J Physiol Regul Integr Comp Physiol. 2007;292:R2179-R2187.
35. Liu JL, Murakami H, Zucker IH. Effects of NO on baroreflex control of heart rate and renal nerve activity in conscious rabbits. Am J Physiol. 1996;270(6 pt 2):R1361-R1370.
36. Liu JL, Murakami H, Zucker IH. Angiotensin II-nitric oxide interaction on sympathetic outflow in conscious rabbits. Circ Res. 1998;82:496-502.
37. Zucker IH, Liu JL. Angiotensin II-nitric oxide interactions in the control of sympathetic outflow in heart failure. Heart Fail Rev. 2000;5:27-43.
38. Mitra AK, Gao L, Zucker IH. Angiotensin II-induced upregulation of AT(1) receptor expression: sequential activation of NF-κB and Elk-1 in neurons. Am J Physiol, Cell Physiol. 2010;299:C561-C569.
39. Hiroki J, Shimokawa H, Higashi M, Morikawa K, Kandabashi T, Kawamura N, Kubota T, Ichiki T, Amano M, Kaibuchi K, Takeshita A. Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol. 2004;37:537-546.
40. Patel KP, Zhang K, Zucker IH, Krukoff TL. Decreased gene expression of neuronal nitric oxide synthase in hypothalamus and brainstem of rats in heart failure. Brain Res. 1996;734:109-115.
41. Liu D, Gao L, Roy SK, Cornish KG, Zucker IH. Role of oxidant stress on AT1 receptor expression in neurons of rabbits with heart failure and in cultured neurons. Circ Res. 2008;103:186-193.
42. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res. 2004;95:937-944.
43. Brändle M, Wang W, Zucker IH. Hemodynamic correlates of baroreflex impairment of heart rate in experimental canine heart failure. Basic Res Cardiol. 1996;91:147-154.
44. Head GA. Baroreflexes and cardiovascular regulation in hypertension. J Cardiovasc Pharmacol. 1995;26(suppl 2):S7-16.
45. Wei SG, Yu Y, Zhang ZH, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009;296:H1425-H1433.
46. Lindley TE, Infanger DW, Rishniw M, Zhou Y, Doobay MF, Sharma RV, Davisson RL. Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction. Am J Physiol Regul Integr Comp Physiol. 2009;296: R1-R8.
47. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004;109:120-124.
48. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976;294:1165-1170.
49. Esler M, Kaye D. Increased sympathetic nervous system activity and its therapeutic reduction in arterial hypertension, portal hypertension and heart failure. J Auton Nerv Syst. 1998;72:210-219.
50. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci. 2001;940:431-443.
51. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H, Takeshita A. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res. 2003;92: 1337-1343.
52. Meredith IT, Broughton A, Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med. 1991;325:618-624.
53. Roveda F, Middlekauff HR, Rondon MU, Reis SF, Souza M, Nastari L, Barretto AC, Krieger EM, Negrão CE. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol. 2003;42:854-860.
54. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321-1328.